1. Scrip

Intercept Unlikely To Refile OCA For NASH Before Late 2021

 
• By Joseph Haas

Once determined to resubmit its NDA by the end of 2020, Intercept now says talks with the FDA have presented a new path to approval in non-alcoholic steatohepatitis that could mean refiling sometime in 2021.

Binocular viewer_1200X675
Intercept can see a path forward in NASH, but it will take a while

Intercept Pharmaceuticals, Inc.’s announcement that it hopes to refile the new drug application for obeticholic acid, its non-alcoholic steatohepatitis drug candidate, sometime in 2021 dramatically changes the timeline for the drug’s potential approval, but investors responded positively to the news, perhaps indicating relief that a clear path to approval now seems to be in place.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 
• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.